公开(公告)号：KR1020120002943A

公开(公告)日：2012-01-09

申请号：KR1020110065151

申请日：2011-06-30

Applicant: 포항공과대학교 산학협력단

Inventor： 고용송 ,  김오연 ,  장수철 ,  윤창민 ,  김윤근

IPC: A61K39/085 ,  A61K38/16 ,  A61K38/12 ,  A61K47/48 ,  A61K49/00 ,  A61K9/50 ,  A61K31/616 ,  A61K31/704 ,  A61K47/46 ,  A61K39/00

CPC classification number: A61K35/74 ,  A61K9/5068 ,  A61K31/616 ,  A61K31/704 ,  A61K38/12 ,  A61K38/164 ,  A61K47/46 ,  A61K47/6901 ,  A61K49/0017 ,  A61K49/0045 ,  A61K49/0097 ,  A61K2039/585 ,  A61K39/085

Abstract: PURPOSE: A method for treating and/or diagnosing cancer using bacteria-derived micro vesicles is provided to enhance anti-cancer efficiency and to reduce side effect to a therapeutic agent. CONSTITUTION: A pharmaceutical composition for treating or diagnosing cancer contains bacteria-derived microvesicles. The bacteria express a material for treating or diagnosing cancer and a material for targeting cancer cells or tissues. The composition additionally contains a drug for inhibiting toxicity by the micro vesicles. The drug is loaded to the micro vesicles. The drug is polymyxin B or aspirin. The membrane of the micro vesicle is modified chemically. A method for preparing the microvesicle comprises: a step of adding the drug to suspension containing the bacteria or transformed bacteria or mixture suspension containing the bacteria or transformed bacteria and drug; and a step of isolating loaded micro vesicles.

Abstract translation: 目的：提供使用细菌衍生的微囊泡治疗和/或诊断癌症的方法，以提高抗癌效率并降低对治疗剂的副作用。 构成：用于治疗或诊断癌症的药物组合物含有细菌来源的微泡。 细菌表达用于治疗或诊断癌症的材料和用于靶向癌细胞或组织的材料。 组合物另外含有用于抑制微囊泡毒性的药物。 将药物装载到微囊泡中。 该药物是多粘菌素B或阿司匹林。 微囊的膜被化学修饰。 制备微泡的方法包括：将药物加入含有细菌或转化细菌的悬浮液或含有细菌或转化细菌和药物的混合悬浮液中的步骤; 以及分离加载的微囊泡的步骤。

公开(公告)号：KR1020070007779A

公开(公告)日：2007-01-16

申请号：KR1020067015541

申请日：2004-12-30

Applicant: 포항공과대학교 산학협력단 ,  주식회사 포스코

Inventor： 채치범 ,  고용송 ,  나찬현 ,  전상희

IPC: C07K7/00 ,  C07K7/06

CPC classification number: C07K14/4711 ,  A61K38/00 ,  C12Q1/37 ,  G01N2333/4709 ,  G01N2500/02

Abstract: A polypeptide for selectively inhibiting amyloid precursor protein(APP) processing is provided to be applied to a subject to require the APP, thereby treating symptoms of Alzheimer's disease. The polypeptide combines to beta-secretase cleavage site of an amyloid precursor protein and contains about 4 to 20 amino acids, where the beta-secretase cleavage site is located within SEVKMDAEFR(SEQ ID NO : 1) or SEVNLDAEFR (SEQ ID NO : 2). The polypeptide combines to gamma-secretase cleavage site of amyloid precursor protein and contains about 4 to 20 amino acids, where the gamma-secretase cleavage site is located within GWIATVIVI (SEQ ID NO : 8). The method for preventing binding between APP and beta-secretase or gamma-secretase comprises a step of providing a compound which inhibits the interaction between APP and beta-secretase or the interaction between APP and gamma-secretase.

Abstract translation: 提供了用于选择性抑制淀粉样蛋白前体蛋白（APP）处理的多肽以应用于受试者以需要APP，从而治疗阿尔茨海默病的症状。 该多肽与淀粉样蛋白前体蛋白的β-分泌酶切割位点结合并且含有约4至20个氨基酸，其中β-分泌酶切割位点位于SEVKMDAEFR（SEQ ID NO：1）或SEVNLDAEFR（SEQ ID NO：2） 。 该多肽与淀粉样蛋白前体蛋白的γ-分泌酶切割位点结合并且含有约4至20个氨基酸，其中γ-分泌酶切割位点位于GWIATVIVI（SEQ ID NO：8）内。 用于预防APP和β-分泌酶或γ-分泌酶之间的结合的方法包括提供抑制APP和β-分泌酶之间的相互作用的化合物或APP与γ-分泌酶之间的相互作用的步骤。